MALIGNANT PLEURAL MESOTHELIOMA - A DISEASE UNAFFECTED BY CURRENT THERAPEUTIC MANEUVERS
MALIGNANT PLEURAL MESOTHELIOMA - A DISEASE UNAFFECTED BY CURRENT THERAPEUTIC MANEUVERS
复制标题
DOI：
10.1200/jco.1988.6.3.527
复制
发表时间：
1988-03-01
影响因子：
45.3
通讯作者：
VANDERMERWE, CA
中科院分区：
文献类型：
--
作者：
ALBERTS, AS;FALKSON, G;VANDERMERWE, CA
自1965~1985年间，262例恶性胸膜间皮瘤患者接受了单纯细胞抑素、放疗、放疗加细胞抑素或去角质层加放疗加细胞抑素治疗。中位生存期(MS)为9.6个月。这对所有可比的治疗组来说都是相似的。在单因素分析中，显著有利的预后因素是良好的表现状态(PS)、确诊时的症状持续时间和6个月、疾病早期、白人和女性。在多变量分析中，PS、种族、症状持续时间和分期对良好的预后有重要意义。在本研究中，年龄、首发症状为疼痛、组织学亚型和放疗剂量对预后无意义。逐步增加治疗方式并没有增加存活率，这与报道的未经治疗的患者的存活率相同。因此，新药物的第二阶段试验为这种疾病的治疗提供了唯一的希望。
From 1965 to 1985, 262 patients with malignant pleural mesothelioma were treated with cytostatics only; radiotherapy (RT); RT and cytostatics; or decortication plus RT plus cytostatics. The median survival (MS) from diagnosis was 9.6 months. This was similar for all comparable treatment groups. In a univariate analysis, significant favorable prognostic factors were good performance status (PS), duration of symptoms > 6 months at the time of diagnosis, early stage of disease, white race, and female sex. In a multivariate analysis, PS, race, duration of symptoms, and stage were of significance for a favorable prognosis. Age, pain as first symptom, histologic subtype, and RT dose were not of prognosis significance in this study. The stepwise addition of treatment modalities did not increase survival, which remained the same as that reported for untreated patients. Therefore, phase II trials of new agents offer the only hope for advance in the treatment of this disease.